Most CML patients express either e13a2 or e14a2 BCR-ABL1 fusion transcripts, but approximately 5% of patients express variant transcripts that may involve fusion of alternative exons, insertions, or breakpoints within exons. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.